BioCentury
ARTICLE | Clinical News

DPK-060: Phase II data

December 24, 2012 8:00 AM UTC

Top-line data from a double-blind, placebo-controlled, Swedish Phase II trial in 69 patients with acute external otitis caused by bacterial or fungal pathogens showed that thrice-daily DPK-060 2% ear drops for 7-10 days was safe and well tolerated for topical treatment in the outer auditory channel. DPK-060 also met the secondary endpoint of improving the clinical cure rate at day 10 vs. placebo. Specifically, DPK-060 led to complete cure in 85-94% of patients depending on the rating scale used. Pergamum said it will begin seeking a partner for DPK-060 in 2013. DPK-060 has also completed a Phase II trial in atopic dermatitis. ...